43 related articles for article (PubMed ID: 37788323)
1. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
Zuo D; Zhu Y; Wang K; Qin Y; Su Y; Lan S; Li Y; Dong S; Liang Y; Feng M
Biomed Pharmacother; 2024 May; 175():116782. PubMed ID: 38776682
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of USP7 enhances CD8
Sun LL; Zhao LN; Sun J; Yuan HF; Wang YF; Hou CY; Lv P; Zhang HH; Yang G; Zhang NN; Zhang XD; Lu W
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38589688
[TBL] [Abstract][Full Text] [Related]
3. Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity.
Adam K; Lipatova Z; Abdul Ghafoor Raja M; Mishra AK; Mariuzza RA; Workman CJ; Vignali DAA
J Immunol; 2024 May; ():. PubMed ID: 38775415
[TBL] [Abstract][Full Text] [Related]
4. Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function.
Silberstein JL; Du J; Chan KW; Frank JA; Mathews II; Kim YB; You J; Lu Q; Liu J; Philips EA; Liu P; Rao E; Fernandez D; Rodriguez GE; Kong XP; Wang J; Cochran JR
Proc Natl Acad Sci U S A; 2024 Mar; 121(12):e2310866121. PubMed ID: 38483996
[TBL] [Abstract][Full Text] [Related]
5. CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker.
Mishra AK; Shahid S; Karade SS; Agnihotri P; Kolesnikov A; Hasan SS; Mariuzza RA
Structure; 2023 Oct; 31(10):1149-1157.e3. PubMed ID: 37619561
[TBL] [Abstract][Full Text] [Related]
6. Discovery of First-in-Class Small Molecule Inhibitors of Lymphocyte Activation Gene 3 (LAG-3).
Abdel-Rahman SA; Rehman AU; Gabr MT
ACS Med Chem Lett; 2023 May; 14(5):629-635. PubMed ID: 37197466
[TBL] [Abstract][Full Text] [Related]
7. FGL1 and FGL2: emerging regulators of liver health and disease.
Chen J; Wu L; Li Y
Biomark Res; 2024 May; 12(1):53. PubMed ID: 38816776
[TBL] [Abstract][Full Text] [Related]
8. Interrogating ligand-receptor interactions using highly sensitive cellular biosensors.
Funk MA; Leitner J; Gerner MC; Hammerler JM; Salzer B; Lehner M; Battin C; Gumpelmair S; Stiasny K; Grabmeier-Pfistershammer K; Steinberger P
Nat Commun; 2023 Nov; 14(1):7804. PubMed ID: 38016944
[TBL] [Abstract][Full Text] [Related]
9. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.
Mariuzza RA; Shahid S; Karade SS
J Biol Chem; 2024 May; 300(5):107241. PubMed ID: 38556085
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Ruffo E; Wu RC; Bruno TC; Workman CJ; Vignali DAA
Semin Immunol; 2019 Apr; 42():101305. PubMed ID: 31604537
[TBL] [Abstract][Full Text] [Related]
11. The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif.
Aigner-Radakovics K; De Sousa Linhares A; Salzer B; Lehner M; Izadi S; Castilho A; Pickl WF; Leitner J; Steinberger P
Sci Signal; 2023 Oct; 16(805):eadg2610. PubMed ID: 37788323
[TBL] [Abstract][Full Text] [Related]
12. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
Ming Q; Celias DP; Wu C; Cole AR; Singh S; Mason C; Dong S; Tran TH; Amarasinghe GK; Ruffell B; Luca VC
Nat Immunol; 2022 Jul; 23(7):1031-1041. PubMed ID: 35761082
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.
Shapiro M; Herishanu Y; Katz BZ; Dezorella N; Sun C; Kay S; Polliack A; Avivi I; Wiestner A; Perry C
Haematologica; 2017 May; 102(5):874-882. PubMed ID: 28154084
[TBL] [Abstract][Full Text] [Related]
14. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation.
Guy C; Mitrea DM; Chou PC; Temirov J; Vignali KM; Liu X; Zhang H; Kriwacki R; Bruchez MP; Watkins SC; Workman CJ; Vignali DAA
Nat Immunol; 2022 May; 23(5):757-767. PubMed ID: 35437325
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
